Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cope

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
European Journal of Immunology|May 17, 2013
CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent mannerBehdad Afzali, Peter J Mitchell, Francis C Edozie, et al.
Annals of the Rheumatic Diseases|August 7, 2021
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritisKulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases|June 9, 2022
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogrammingFaye A H Cooles, Jessica Tarn, Dennis W Lendrem, et al.
Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.
Rheumatology (Oxford, England)|November 6, 2023
Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flaresMark D Russell, Louise Ameyaw-Kyeremeh, Flora Dell'Accio, et al.
Science (New York, N.Y.)|June 18, 2016
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cellsGiuseppina Arbore, Erin E West, Rosanne Spolski, et al.
Lancet (London, England)|February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Annals of the Rheumatic Diseases|March 6, 2012
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisDanielle M Gerlag, Karim Raza, Lisa G M van Baarsen, et al.
Trials|July 17, 2019
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocolMariam Al-Laith, Marianna Jasenecova, Sonya Abraham, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
European Journal of Immunology|May 17, 2013
CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent mannerBehdad Afzali, Peter J Mitchell, Francis C Edozie, et al.
Annals of the Rheumatic Diseases|August 7, 2021
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritisKulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases|June 9, 2022
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogrammingFaye A H Cooles, Jessica Tarn, Dennis W Lendrem, et al.
Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.
Rheumatology (Oxford, England)|November 6, 2023
Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flaresMark D Russell, Louise Ameyaw-Kyeremeh, Flora Dell'Accio, et al.
Science (New York, N.Y.)|June 18, 2016
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cellsGiuseppina Arbore, Erin E West, Rosanne Spolski, et al.
Lancet (London, England)|February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Annals of the Rheumatic Diseases|March 6, 2012
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisDanielle M Gerlag, Karim Raza, Lisa G M van Baarsen, et al.
Trials|July 17, 2019
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocolMariam Al-Laith, Marianna Jasenecova, Sonya Abraham, et al.
Pageof 19